
|Videos|November 14, 2020
AAO: Study confirms Phase III results for uveitis treatment
Author(s)OTE Staff Reports
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Advertisement
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Clinical pearls for detecting pre-perimetric glaucoma
2
Broadening horizons: Expanding your surgical portfolio with SMILE pro for Hyperopia
3
IGS 2026: The expanding role of artificial intelligence in ophthalmology
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5




























